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The discovery of Akkermansia muciniphila has opened new avenues for the use of this abundant intestinal
symbiont in next generation therapeutic products, as well as targeting microbiota dynamics.
A. muciniphila is known to colonize the mucosal layer of the human intestine where it triggers both host
metabolic and immune responses. A. muciniphila is particularly effective in increasing mucus thickness
and increasing gut barrier function. As a result host metabolic markers ameliorate. The mechanism of
host regulation is thought to involve the outer membrane composition, including the type IV pili of
A. muciniphila, that directly signal to host immune receptors. At the same time the metabolic activity of
A. muciniphila leads to the production of short chain fatty acids that are beneficial to the host and
microbiota members. This contributes to host-microbiota and microbe-microbe syntrophy The mucolytic
activity and metabolite production make A. muciniphila a key species in the mucus layer, stimulating
beneficial mucosal microbial networks.
This well studied member of the microbiota has been studied in three aspects that will be further
described in this review: i) A. muciniphila characteristics and mucin adaptation, ii) its role as key species
in the mucosal microbiome, and iii) its role in host health.
© 2017 Published by Elsevier Ltd.Introduction
In recent years, it has become evident that the intestinal
microbiota can play an essential role in the well being of humans.
The composition of microbial communities colonizing the gastro-
intestinal tract differs according to the prevailing environmental
conditions in the gut. Factors such as nutrient supply, transit time,
host secretions, and pH play a role in shaping the gut microbiota
[1]. In particular, the mucosa-associatedmicrobiota forms a distinct
population in the gut, and is influenced by the close proximity of
the epithelial layer and nutrients present in the mucus layer [2e5].
One of the key players in this community is the mucus degrader
Akkermansia muciniphila, which has been shown to have important
implications on host physiology and microbiome composition
[6e8].
The Gram-negative bacterium A. muciniphilawas isolated from ahuman fecal sample in a quest to discover new mucin-degrading
bacteria [9]. As A. muciniphila is the only intestinal isolate of the
deeply rooted Verrucomicrobia phylum, it can be easily detected in
meta-omics studies [10]. A. muciniphila represents 1e4% of the total
fecal microbiota starting from early life [11,12], and biopsies show it
to be abundantly present in the colonic mucosal layer [13,14]. After
its discovery, the levels of A. muciniphila in the gut were negatively
correlated with numerous diseases, including inflammatory bowel
diseases (IBD) [13,15], appendicitis [16], obesity [17,18] and diabetes
[19]. Further mechanistic studies have shed more light on the anti-
inflammatory role of A. muciniphila in the gut environment [6,7,20].
Based on these findings, A. muciniphila or its components have
been suggested to be a promising candidate for next-generation
therapeutic products [21,22]. Currently the most convincing evi-
dence of its beneficial effect on health comes from studies linking
A. muciniphila to metabolic disorders, such as diabetes and obesity.
However, the exact signaling mechanisms by which A. muciniphila
interacts with the host, and the effect it has on the overall microbial
community in the gut, require further investigation. Here, we
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istics and mucin adaptation, ii) A. muciniphila role as key species in
the mucosal microbiome, and iii) A. muciniphila role in host health
(Fig. 1).
A. muciniphila characteristics and mucin adaptation
To gain a competitive advantage in the gut environment, certain
bacteria have evolved to metabolize the complex glycans provided
by the mucus layer. A. muciniphila encodes a particularly wide
repertoire of mucin-degrading enzymes in its relatively small 2.6-
Mb genome [23], and can be described as a mucin specialist. As
opposed to for example Bacteroides thetaiotaomicron, a glycan
generalist [24]. This notion is backed up by the observation that the
mucin-degrading genes are conserved in other A. muciniphila
strains and Akkermansia species described thus far [25]. Mucus
colonization and degradation by A. muciniphila result in the pro-
duction of metabolites such as short-chain fatty acids (SCFA), which
may play a role in metabolic heath or inflammatory status of theFig. 1. Three key functions of A. muciniphila in the microbiome thathost [26]. The relative abundance of A. muciniphila in the gut is
highly responsive to changes. As such, dietary fiber deprivation,
weight loss and anorexia increase its levels in the gut [27e29],
while a high fat diet decreases it levels [30].
While A. muciniphila is able to individually metabolize mucin-
derived sugars, such as fucose and N-acetylglucosamine (GlcNAc)
in a basal mediumwith among others large amounts of tryptone, it
grows most efficiently when it has access to the entire mucin
molecule [31]. Unlike all other members of the Verrucomicrobia,
A. muciniphila cannot synthesize threonine. This is yet another
indication of its adaptation to life in the mucosal layer, as threonine
is one of the most abundant amino acids present in the protein
backbone of mucin [32]. Among the mucin-derived sugars, growth
on GlcNAc and N-acetylgalactosamine (GalNAc) leads to the highest
yields. However, when A. muciniphila is grown on a mixture of
GlcNAc, GalNAc, fucose and glucose, a non-mucin sugar, it first
consumes the non-amino sugars [31]. This may reflect the ease of
transport and efficient energy generation of these simple sugars,
while GlcNAc and GalNAc are used as nitrogen sources.could be targets for probiotic and pharmabiotic interventions.
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A. muciniphila transcriptome and proteome as shown in recent
studies [20,27,31]. Numerous genes encoding glycosyl hydrolases
and sulfatases that are likely to be involved in mucin degradation
were upregulated during A. muciniphila growth on mucin as
compared to growth on glucose, and a similar responsewas seen on
the proteome level [31]. Likewise, growth on purified mucin O-
glycans activated A. muciniphila genes involved in mucin degrada-
tion as compared to growth on GlcNAC, although fewer genes were
identified in this case [27]. Environmental variation was also seen
in the outer membrane (OM) proteome of A. muciniphila,where the
abundance of one third of the OM proteins was different between
bacterial cells grown on either mucin or glucose [33].
A. muciniphila belongs to the Planctomycetes-Verrucomicrobia-
Chlamydiae (PVC) superphylum, which contains several members
with a compartmentalized cell plan as opposed to a typical Gram-
negative membrane architecture [34]. However, a high abundance
of proteins involved in OM biogenesis and lipopolysaccharide (LPS)
transport were detected in the A. muciniphila OM proteome, sup-
porting structural features commonly present in Gram-negative
bacteria [33]. Importantly, analysis of the OM revealed highly
abundant proteins predicted to be involved in the formation of the
pili-like structures observed in A. muciniphila. Further studies
showed that a single protein, termed Amuc_1100 and encoded by a
gene cluster also coding for the type 4 pilin secretin Amuc_1098
[33], plays an important role in the capacity of A. muciniphila to
alleviate metabolic syndrome in mice [7]. These findings highlight
the importance of detailed characterization of intestinal bacteria in
order to understand the mechanisms behind their reported bene-
ficial effects on the host.
Although A. muciniphila was initially described as strictly
anaerobic, it was later discovered to tolerate oxygen [35], and can
even benefit from the presence of nanomolar concentrations of
oxygen by respiration via a rudimentary electron transport chain
[36]. These observations are in line with the fact that A. muciniphila
colonizes the mucus layer close to the epithelial cells, where low
levels of oxygen are present. Oxygen tolerance, along with efficient
mucin degradation capacity, demonstrates the adaptation of
A. muciniphila to the competitive environment of the mucosal layer.
The high efficiency of A. muciniphila in foraging host-derived
compounds has been demonstrated also in vivo in a study using
stable isotope-labeled threonine in a mouse model [37]. The study
found that despite the fairly low relative abundance of Akkermansia
spp. in the mouse cecum, it was, together with Bacteroides acid-
ifaciens and Mucispirillum shaedleri, the dominant forager of host-
derived proteins.A. muciniphila - key species in the mucosal microbiome
Themucus layer is a niche in the intestine, which is colonized by
specific bacteria. The key species within this mucosal community
are able to degrade mucin sugars and the protein backbone [4,5].
The mucus layer consists of a outer gel-forming layer, that provides
a habitat for bacteria, and an inner layer, that is devoid of bacteria
[38,39]. MUC2 is the most abundant gel-forming mucin type in the
intestine and it is constructed of a PTS backbone with O-linked
glycans [40]. The diverse structure and the different linkages within
the glycan chainmake it difficult for most micro-organisms to acces
the amino acids and mono-saccharides. While for mucin degrading
microorganisms it can be used as a source of carbon, energy and
nitrogen [5,9,41,42]. Certain specialists, like B. thetaiotaomicron and
A. muciniphila, have specific enzymes to degrade these mucins
[9,13,43,44]. Especially the sialidases and fucosidases play animportant role in mucin degradation, since most of the terminal
ends of these oligosaccharide chains are sialic acids or fucose [41].
Sialidases and fucosidases are not commonly encoded in the met-
agenome of the microbiota. These terminal sugars are thought
prevent comprehensive microbial utilization of mucin [45]. The
other sugars in the oligosaccharide chain are more easily degraded
by members of the microbiota [45].
It should be noted that not all microbes that are found in the
mucus layer have the ability degrade mucin. They depend on the
mucolytic activity of other microbiota members to colonize the
mucus layer [46]. Degradation of the mucin protein backbone and
the release of sugars from the glycan chains, provide carbon and
nitrogen for the bacteria that do not produce these enzymes
[23,47]. The butyrate-producers Faecalibacterium prausnitzii, Eu-
bacterium rectale, Roseburia intestinalis and Anaerostipes caccae are
examples of species that do not have the ability to degrade mucus,
but are commonly found in the mucus layer [8,48e50]. Since
butyrate is a source of energy for the colonocytes, the production of
butyrate by these organisms nearby the epithelium layer is a useful
benefit for the host [51e53]. An actual syntrophy between
A. muciniphila and various butyrate producers was shown in vitro.
The mucolytic activity of A. muciniphila lead to accumulation of
acetate and mono-saccharides in the medium. These were fer-
mented to butyrate by the cross feeding butyrogens A. caccae, Eu-
bacterium hallii and F. prausnizii [8]. Furthermore, when
A. muciniphila and E. halliiwere co-cultured there was a mutualistic
relationship to the benefit of both partners. E. hallii produced
pseudovitamin B12 which stimulated the methylmalonyl pathway
and hence propionate production of A. muciniphila [8]. At the same
time, A. muciniphila also produced 1,2 propanediol from fucose
which was metabolized by E. hallii to propionate [8,54,55]. Both of
these conversions resulted in the production of propionate, which
plays an important role in host gut homeostasis and satiety [52].
Another functional symbiosis of this mucosal key species might
be the sulfate that A. muciniphila was found to release from the
mucin [56]. A. muciniphila abundantly produces sulfatases during
mucin degradation [20]. Sulfate reducing bacteria (SRB) are vast
colonizers of the mucosal layer of the colon [57]. An in vitro study
showed that SRB'smay reduce the sulfate released frommucin [58].
Even though these SRB are positively associated with inflammation
[59], the actual correlation between hydrogen sulfide and diseases
still needs more research, notably since hydrogen sulfide is also
neurotransmitter [60,61]. Interestingly, A. muciniphila might be
able to use hydrogen sulfide for cysteine production, because the
cysteine biosynthesis pathway is predicted in the genome, where it
uses hydrogen sulfide for the production of L-cysteine. In this way it
could control hydrogen sulfide concentrations and potentially limit
the toxicity of SRB in the mucin layer.
The microbial ecology at the mucosal layer is essential in un-
derstanding the role of the microbiota in health and disease.
A. muciniphila can be considered a key species of the mucosal layer,
providing the microbial community with mono- and oligosaccha-
rides, SCFA production, and by detoxifying hydrogen sulfide. How
the actual mucosal microbial community reaches its stability and is
associated with mucosal health needs further investigation.A. muciniphila host interaction and health
The presence of A. muciniphila in the gut was found to be
correlated to a healthy intestine and inversely correlated to many
states of disease [13,15e19]. The studies that report a negative
correlation of A. muciniphila abundance with disease include in-
testinal disorders, such IBD, but also other diseases, such as autism,
N. Ottman et al. / Best Practice & Research Clinical Gastroenterology 31 (2017) 637e642640atopy, and obesity and related diseases. The majority of studies
however, have addressed a beneficial role of Akkermansia spp in the
prevention and amelioration of metabolic syndrome. As such,
A. muciniphila is one of the few microbiota members that is shown
to have an actual causal relationship with improved host health in
mouse models [7]. Unfortunately, the culturing and preserving
techniques for A. muciniphila are not yet sufficient for it to be used
as a supplement. However, current A. muciniphila research also
focuses on the preparation and preservation process of viable and
pasteurized cells and cell products for their use in therapeutic in-
terventions [7,62,63].
In terms of microbiota as a potential therapeutic target, the
latest data suggest that A. muciniphila could potentially be used in
treatment for type 2 diabetes (T2D) [64]. In a first study, a decrease
of A. muciniphilawas observed in leptin-deficient mice compared to
lean mice [6,30]. In addition, a decrease of A. muciniphila, to a lesser
extent than in obese mice, was also found in mice supplemented
with a high-fat diet (HFD) that are obese and develop T2D-like
symptoms [6,65,66]. The administration of A. muciniphila to HFD-
fed mice without administration of metformin, which lowers the
glucose levels in blood, resulted in a significantly enhanced glucose
tolerance and weakened adipose tissue inflammation. Treatment of
mice with either live or pasteurized A. muciniphila cells further
strengthens the evidence of the effect of this microorganism on
metabolic and immune health [7]. Ex vivo experiments usingmouse
gut organoids showed that A. muciniphila metabolites specifically
affect various transcription factors and genes involved in cellular
lipidmetabolism and satiety [67]. Based on these results, increasing
Akkermansia levels in the gut could influence anti-diabetic effects of
the anti-diabetic drug metformin. In fact metformin was found to
increase the levels of Akkermansia spp populations in mice both on
a HFD and normal diet [64,68]. In humans Akkermansia spp was
found to be more abundant in T2D patients compared to healthy
controls [69]. However, in newly diagnosed T2D and pre-diabetes
patients, a lower abundance of Akkermansia spp was observed
[19]. The differential results in these studies could be due to met-
formin, which can stimulate A. muciniphila [64,68]. Preliminary
results of a human clinical trial treating obese individuals with
A. muciniphila indicated this organism can be safely used in humans
[7]. Altogether, these studies indicate a health-promoting role of
A. muciniphila, leading to its possible use as a therapeutic microbe.
The abundance of A. muciniphilawas also found to be negatively
correlated to dietary fat intake [70]. Treatment of mice with
A. muciniphila normalized diet-induced metabolic endotoxaemia,
adiposity and the adipose tissue markers [6]. Furthermore, the
A. muciniphila treatment resulted in reduced body weight gain and
body composition even though the food intake did not change [6].
In humans an improved metabolic profile was observed for in-
dividuals harboring more A. muciniphila at baseline [18]. In addi-
tion, a negative association of A. muciniphila with serum total and
LDL cholesterol was found in obese Danish women. The reduction
in gluconeogenesis and insulin resistance index suggests a key role
of A. muciniphila in metabolic inflammation, barrier function and
fat storage [6].
A compromised gut barrier function is associated with diseases
such as IBD and metabolic syndrome. The majority of human
studies observed A. muciniphila depletion in IBD mucosa and fecal
samples of patients suffering from ulcerative colitis [13,71]. The
abundance of A. muciniphilawas found to be positively correlated to
the level of mucins in cecum of rodents [72]. A. muciniphila is able
to degrade mucins, but was also found to stimulate mucin pro-
duction, mucus thickness, and gut barrier [6,64]. In addition, it was
also suggested that the restoration of the gut barrier byA. muciniphila debilitated atherosclerotic lesions and alleviated
inflammation induced by metabolic endotoxaemia [73]. Overall,
treatment of mice with A. muciniphila resulted in an improved gut
barrier function [6,62,71].
A. muciniphila is also described to regulate the immune system
which leads to production of antimicrobial peptides and improved
gut homeostasis. Administration of A. muciniphila resulted in an
enhanced production of antimicrobial peptide Reg3g in the colon
and to lesser extent the ileum [6,74]. In addition, A. muciniphilawas
found to stimulate the proliferation of anti-inflammatory Treg cells
inmice [64]. In an in vitro colonic cell line, A. muciniphila adhered to
the epithelium and strengthened the intestinal barrier, where a low
pro-inflammatory response was induced in comparison to E. coli
strain K12 [35]. IgA has a function in elimination of pathogens and
maintaining homeostasis [75]. Inoculation of A. muciniphila
together with Clostridium scindens in mice prevented lethality and
resulted in reduced detachment of epithelial cells in mice colonized
with a variety of bacteria targeted by IgA [76]. Host regulation by
A. muciniphila was shown to at least partially depend on its outer
membrane proteins that includes abundant proteins involved in
transport/secretion and proteins with a role in the formation of pili-
like structures [20]. The highly abundant outer membrane pili-like
protein (Amuc_1100) of A. muciniphila type strain MucT was
identified [20]. Amuc_1100 is directly involved in immune regula-
tion and enhances trans-epithelial resistance. These studies indi-
cate an active communication between A. muciniphila and the host
immune system.
Altogether, these studies suggest the usefulness of
A. muciniphila as therapeutic treatment for intestinal disorders by
the capability to regulate host metabolic response and to increase
gut barrier function.Summary and conclusions
Themicrobiome has become an important target formodulating
host health. A. muciniphila is one of the few microbiota members
proven to have a direct and beneficial effect on host response
(Fig. 1). This microorganism is shown to be effective in immune and
metabolic regulation, combined with increase gut barrier function.
These effects will lead to overall increased gut andmetabolic health
of the host. The mechanism underlying the host regulatory effects
of A. muciniphila are described to be through direct signaling of OM
proteins and production of metabolites, as well as through stimu-
lation of a beneficial microbial community (Fig. 1). The core func-
tions of A. muciniphila physiology due to mucin degradation are
production of acetate, propionate, and 1,2-propanediol. Mucin
degradation by A. muciniphila attracts microbiota members that
stimulate host health by for example the production of butyrate
and prevention of pathogen colonization. There are clear advances
in research focused on A. muciniphila in comparison to other in-
testinal isolates, because a defined medium and optimized culture
conditions have been developed to produce this organism for
intervention studies. On top of this the organism is reported to be
safe for the use in human trials and the first clinical trial has even
been conducted [7]. While various genetic improvements of A.
muciniphila may be considered, the present regulations on genet-
ically modified micro-organisms do not allow easy market intro-
duction of such improved bacteria in countries of the European
Union. Future research should focus on the mechanism on how
A. muciniphila effectively modulates the microbiome and host
response to find the right way of use for this organism in thera-
peutic applications.
N. Ottman et al. / Best Practice & Research Clinical Gastroenterology 31 (2017) 637e642 641Practice points A. muciniphila cannot grow without mucin-derived ami-
nosugars and threonine
 A. muciniphila uses the low oxygen levels at the mucosa
for respiratory growth
 Mucosal colonization by A. muciniphila enables associa-
tion with other beneficial microbes such a various
butyrogens
 A decrease in abundance of A. muciniphila is found dur-
ing metabolic syndrome in both preclinical and clinical
studies
 Intervention studies with A. muciniphila have reported
beneficial impact on host metabolism
 Living as well as pasteurized cells and the pili protein
Amuc_1100 of A. muciniphila are involved in host meta-
bolic regulationResearch agenda Future possibilities of A. muciniphila manipulation
should make it a model organism for Verrucomicrobia in
the microbiome
 The role of A. muciniphila in microbiome ecology should
be further investigated
 Further research should focus on the metabolic regula-
tion in humans
 More insight is needed into the underlying mechanisms
of A. muciniphila host metabolic regulationConflict of interest
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